CSBR vs FRT · P/E 16, rev $56.9M vs rev $1.28B
Champions Oncology Inc (CSBR) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Champions Oncology Inc (CSBR) is a biotechnology company listed on US.
FRT (FRT) common stock.
Latest reported CSBR revenue for 2025-04-30 was $56.9M. Net income was $4.7M. CSBR currently screens at market cap $99.8M and trailing P/E 16.0.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
CSBR currently screens at market cap $99.8M and trailing P/E 16.0. FRT currently screens at market cap $0.
Not investment advice. Open the CSBR and FRT stock pages for the full models.
Not investment advice.